• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

One Health: Vision Loss Treatment for Dogs May Benefit Humans

August 30, 2018
Amanda Carrozza

A novel gene therapy has been developed to treat one of the most common forms of retinitis pigmentosa, a disease that causes vision loss in both dogs and humans.

A novel gene therapy proven to halt vision loss in dogs is believed to have One Health potential. The scientists who developed the therapy, which treats a condition that causes blindness called autosomal dominant retinitis pigmentosa (adRP), are hopeful that their strategy may one day be used to delay or halt vision loss in people with the same disease. Retinitis pigmentosa, the most common inherited form of blindness, affects an estimate 60,000 to 100,000 people in the United States.

“We’ve developed and shown proof-of-concept for a gene therapy for one of the most common forms of retinitis pigmentosa,” said William Beltran, DVM, PhD, a professor of ophthalmology at the University of Pennsylvania School of Veterinary Medicine and lead author of the study. The group’s study has been published in the Proceedings of the National Academy of Sciences.

RELATED:

  • One Health to the Rescue: Intracranial Arteriovenous Malformation in a Dog
  • Stem Cell-Derived Retinal Transplants May Improve Vision in Mice with End-Stage Retinal Degeneration
Advertisement

Retinitis pigmentosa refers to a group of inherited diseases that damage photoreceptors in the retina, leading to retinal degeneration. Because more than 150 rhodopsin mutations can cause adRP, developing effective therapies has proved challenging. People with adRP caused by mutations in the rhodopsin gene usually possess a mutated copy of the gene that codes for an abnormal rhodopsin protein. The abnormal protein is often toxic and slowly kills the rod cells that allow for vision in low light.

In a study funded by the National Eye Institute, the investigators were able to develop a gene therapy construct that reduces the rod cells’ ability to produce the abnormal rhodopsin. They did so using a technology known as shRNA interference, which introduces genetic material into cells to compensate for abnormal genes or to make a beneficial protein.

For their initial testing, the investigators used dogs with a rhodopsin mutation. Similar to how the disease affects people, dogs slowly lose their rod photoreceptors and thus their vision. In the dogs’ retinas, the gene therapy eliminated about 98% to 99% of both mutated and normal rhodopsin. However, because normal rhodopsin is required for the rods to detect light, the researchers added a “hardened” shRNA-resistant rhodopsin gene to the same vector.

“The problem is balance,” said Alfred Lewin, PhD, a professor of molecular genetics and microbiology at the University of Florida College of Medicine in Gainesville. “We wanted to be sure that every cell that got the shRNA also got the replacement, so we made a single adeno-associated viral vector that did both.”

When the dogs were treated with the combined vector version of the gene therapy, they maintained healthy, functional photoreceptors. Because the vector was designed to produce human rhodopsin, it has the potential to work in humans as well. The treatment prevents photoreceptor loss rather than promoting regeneration, so it may be helpful for patients who have slowly progressing forms of adRP and whose retinas include areas with living rod cells that can be treated.

The investigators hope to start preclinical safety studies within the next 2 years, with the eventual goal of human trials.


Advertisement

Latest News

Learning more about AmeriVet

Announcing our 2023 Fetch and Directions in Veterinary Medicine continuing education schedule: Biggest event lineup to date

Dogs and staff at Seattle dog resort safely escape fire

Pet safety for this Super Bowl Sunday

View More Latest News
Advertisement